Media ReleaseConfirmed complete response in a patient with metastatic breast cancer refractory to several lines of therapy achieved during ...

Phase 1 study progressing well, anticipate clearing dose-limiting toxicity (DLT) observation period with 1 gram (14.2 mg/kg) in 2Q 2024 and initial Phase 2 monotherapy data readout on track for 2Q ...

Phase 2 data in squamous cell carcinoma of the head and neck (SCCHN) showed multiple confirmed responses and manageable safety profile; anticipate FDA meeting for SCCHN ...

May is Brain Tumor Awareness Month. According to BrainTumor.org, those diagnosed with Glioblastoma have an average survival rate of only 6.9%, with the length of survival estimated to be less than a ...

Discover the latest developments in cancer vaccines as six centers test their effectiveness on pancreatic, breast, glioblastoma, and melanoma.

Arcus Biosciences is preparing for a readout at the ASCO Annual Meeting, which could be a significant catalyst. See why I ...